CN105497051A - Pharmaceutical formula capable of lowering blood glucose and experiment method of pharmaceutical formula - Google Patents
Pharmaceutical formula capable of lowering blood glucose and experiment method of pharmaceutical formula Download PDFInfo
- Publication number
- CN105497051A CN105497051A CN201510902706.1A CN201510902706A CN105497051A CN 105497051 A CN105497051 A CN 105497051A CN 201510902706 A CN201510902706 A CN 201510902706A CN 105497051 A CN105497051 A CN 105497051A
- Authority
- CN
- China
- Prior art keywords
- dose concentration
- group
- baicalin
- blood glucose
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of a pharmaceutical industry and in particular relates to a pharmaceutical formula capable of lowering blood glucose and an experiment method of the pharmaceutical formula. The pharmaceutical formula capable of lowering the blood glucose is prepared from the following raw materials according to concentration ratios: 100mg/kg.d of puerarin, 25mg/kg.d of isoflavoues aglycone, 100mg/kg.d of baicalin, 10mg/kg.d of baicalein, 10mg/kg.d of berberine, 5mg/kg.d of glycyrrhizic acid and 50mg/kg.d of liquiritin. The experiment method of the pharmaceutical formula capable of lowering the blood glucose comprises the following experiment steps: (1) establishing rat hyperglycemia models; (2) sieving and grouping; (3) detecting indicators; (4) analyzing and comparing to obtain a conclusion. The formula provided by the invention is obtained by strict scientific experiments and has very good effects of lowering the blood glucose and improving insulin resistance, can provide a research foundation for secondary development of classic prescriptions and has very high innovation.
Description
Technical field
The present invention relates to pharmaceuticals industry technical field, be specifically related to a kind of hypoglycemic pharmaceutical formulation and experimental technique thereof.
Background technology
Clinical and experimental study report GEGEN QINLIAN TANG has therapeutical effect to diabetes, wherein, the large quantization compound such as flavone, osajin, alkaloids, saponins containing opposed polarity in GEGEN QINLIAN TANG, obtain these materials completely and to carry out comprehensively research very difficult, be which compound is also unclear in action actually.We are according to pertinent literature, have chosen the compound that 7 activity are stronger from GEGEN QINLIAN TANG: the flavonoid 1. deriving from Radix Puerariae: puerarin, daiazi; 2. the flavonoid of Radix Scutellariae is derived from: baicalin, baicalin; 3. the alkaloid of Rhizoma Coptidis is derived from: berberine; 4. the glycyrrhizic acid of Radix Glycyrrhizae, liquirtin is derived from, we have studied 7 compound different ratio to the blood sugar lowering of hyperglycemia model rat and the effect improving insulin resistant, and compare with former prescription and study, find formation and the ratio of best Hypoglycemics.
GEGEN QINLIAN TANG is verified through clinical practice, therapeutic intervention effect is had to type 2 diabetes mellitus and insulin resistant, but compound decoction shortage is to the micro analysis of effective substance and quality control, affect clinical efficacy, the present invention carries out proportion research to the main active of GEGEN QINLIAN TANG, find and optimize the best active component proportioning of GEGEN QINLIAN TANG therapeutic intervention type 2 diabetes mellitus, for the secondary development of this type of classic prescriptions provides Research foundation.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of hypoglycemic pharmaceutical formulation and experimental technique thereof.
For solving the problems of the technologies described above, the invention provides following technical scheme: a kind of hypoglycemic pharmaceutical formulation, described pharmaceutical formulation comprises puerarin, daidzein, baicalin, baicalin, berberine, glycyrrhizic acid, liquirtin seven kinds of medicines, the dose concentration of described puerarin is 50-500mg/kg.d, the dose concentration of daidzein is 10-100mg/kg.d, the dose concentration of baicalin is 10-100mg/kg.d, the dose concentration of baicalin is 10-100mg/kg.d, the dose concentration of berberine is 10-100mg/kg.d, the dose concentration of glycyrrhizic acid is 5-50mg/kg.d, the dose concentration of liquirtin is 10-100mg/kg.d.
Preferably, described pharmaceutical formulation is made up of the crude drug of following matched proportion density: the dose concentration of puerarin 100mg/kg.d, daidzein 25mg/kg.d, baicalin is 100mg/kg.d, the dose concentration of baicalin is 10mg/kg.d, the dose concentration of berberine is 10mg/kg.d, the dose concentration of glycyrrhizic acid is 5mg/kg.d, the dose concentration of liquirtin is 50mg/kg.d.
A kind of experimental technique verifying blood sugar lowering composition formula: comprise following experimental procedure: 1) set up Hyperglycemia In Stz-induced Diabetic Rats model; 2) screening grouping; 3) Testing index; 4) analyze contrast and reach a conclusion.
Preferably, described step 1) in set up Hyperglycemia In Stz-induced Diabetic Rats model number of rats be 110, and be all male rat, above-mentioned 110 male rats are divided into 11 groups by random, often organize 10.
Preferably, described step 2) in screening grouping be divided into 12 groups, be respectively according to eight of GEGEN QINLIAN TANG each extract components proportioning combination N1-N8, Gegen Qinlian Tangyuan County side group N9, metformin group N10, model group N11, original blank group N12.
Preferably, described step 3) in detect index be body weight, fasting glucose, 2h-plasma glucose, glucose filling rate, serum insulin.
Select healthy male 8-9 SD rat in age in week 140, thered is provided by The Fourth Military Medical University's animal experimental center, body weight is between 280 ~ 300g, adaptability feeds 7 days, blank group and model group is divided into by random digits table, blank group 10, model group 130, blank group feeding normal diet, wherein, normal diet is conventional rodent diet, composition is fat 10%, 4 protein 22 %, carbohydrate 68%, salt 0.5%, the high sugared high cholesterol diet of model group feeding height fat, wherein, the high sugared high cholesterol diet formula of high fat is: normal feedstuff 73.8%, Adeps Sus domestica 10%, sucrose 5%, egg yolk 10%, cholesterol 1%, cholate 0.2%, model group and blank group all give common drinking-water, 6 weeks are fed continuously by above-mentioned condition, survey body weight and fasting glucose weekly, 6 weekends surveyed body weight, fasting surveyed fasting glucose after 12 hours, Diagnostic Value of Fasting Serum insulin, calculate insulin resistance index and insulin sensitivity index, SPSS19.0 statistical software is used to carry out data analysis, measurement data mean ± standard deviation in result of the test, employing one factor analysis of variance is compared between many groups, two groups are compared employing t inspection and carry out statistical procedures, P < 0.05 has significance for difference.
The invention has the beneficial effects as follows: the formula in the present invention is through tight scientific experiments and gets, there is the effect well reducing blood glucose, improve insulin resistant, Research foundation can be provided for the secondary development of this type of classic prescriptions, have extremely strong novelty.
Accompanying drawing explanation
Fig. 1 is the block diagram of experimental technique in the present invention;
Fig. 2 is uniform test design figure;
Fig. 3 is the prioritization scheme figure of uniform Design.
Detailed description of the invention
Clearly understand to make object of the present invention, technical scheme and advantage, below in conjunction with drawings and Examples, the present invention is further elaborated, is to be understood that, specific embodiment described herein only in order to explain the present invention, is not intended to limit the present invention.
Experimental program as can be seen from Figure 1 in the present invention is as follows:
1. the foundation of hyperglycemic rat model
1.1 laboratory animal grouping and modelings
Healthy male 8-9 week SD rat in age 140 The Fourth Military Medical University's animal experimental center provide, body weight is between 280 ~ 300g, adaptability feeds 7 days, blank group and model group is divided into by random digits table, blank group 10, model group 130, blank group feeding normal diet, the high sugared high cholesterol diet of model group feeding height fat, model group (RI) and blank group (Normol) all give common drinking-water, 6 weeks are fed continuously by above-mentioned condition, survey body weight and fasting glucose weekly, 6 weekends surveyed body weight, fasting surveyed fasting glucose after 12 hours, Diagnostic Value of Fasting Serum insulin, calculate insulin resistance index and insulin sensitivity index.
1.2 observation index
1.2.1 ordinary circumstance is observed
Observe each group of rat spirit, active state, hair and animal dead situation, use weekly electronic balance weighing rat body weight 1 time, record and analyze body weight change.
1.2.2 blood glucose
Administration the 6th weekend, fasting, after 12 hours, surveys tail vein sugar by blood glucose meter.
1.2.3 Diagnostic Value of Fasting Serum insulin
Survey Diagnostic Value of Fasting Serum insulin by euzymelinked immunosorbent assay (ELISA) (ELISA), modeling the 6th weekend, after fasting 12h, 10% chloral hydrate intraperitoneal injection of anesthesia, socket of the eye venous plexus is taken a blood sample, and gets anticoagulation, 4000r/min, centrifugal 5min, obtains blood plasma.Enzyme linked immunosorbent assay (Enzyme mono-linkedimmunosorbentassay, ELISA) measures Diagnostic Value of Fasting Serum insulin (Fastingseruminsulin, FINS) content.
1.2.4 insulin resistance index
Use HOMA model formation: IRI=GLU × INS ÷ 22.5 calculates insulin resistance index.
1.2.5 insulin sensitivity index
After measuring fasting glucose (FPG) and fasting insulin (FINS) concentration, calculate: insulin sensitivity index (ISI)=Ln [1/ (FPGxFINS)]
1.3 experimental apparatus
ACS-30 electronic price computing scale Yongkang City Hua Ying weighing apparatus company limited
Insulin test kit Beijing North Institute of Biological Technology product
KQ2200DE type numerical control ultrasonic cleaner Kunshan Ultrasonic Instruments Co., Ltd.
TGL-16M table-type high-speed refrigerated centrifuge Changsha Xiang Yi centrifuge Instrument Ltd.
Magnetic force heating stirrer Changzhou Guohua Electric Appliance Co., Ltd.
Electric heating air-blowing drier Shanghai Yiheng Scientific Instruments Co., Ltd
Electronic thermostatic water-bath Beijing Ke Wei Yongxing Instrument Ltd.
HH-S6 type electronic balance Minqiao Precision Scientific Instruments Co., Ltd., Shanghai
4 DEG C of refrigerator Hefei Meiling Co. Ltd.
Insulin test kit Beijing North Institute of Biological Technology product
Pipettor 20 1 200ul, 100 1 EPPendorf companies of 1000ul Germany
Three Nuo Pai blood glucose meter Changsha Sannuo Biology Sensing Technology Co., Ltd
1.4 statistical procedures
SPSS19.0 statistical software is used to carry out data analysis, measurement data mean ± standard deviation in result of the test
represent.Compare between many groups and adopt one factor analysis of variance (ANOVA), two groups are compared and adopt t inspection to carry out statistical procedures, and P < 0.05 has significance for difference.
1.5 experimental result
In ordinary circumstance modeling process, control rats hair color is smooth, submissive, and model group rats activity obviously reduces, lethargy, and chaeta is matt, and modeling, after 6 weeks, according to Testing index, rejects the rat that modeling is unsuccessful and dead.Comparatively, in 2-5 week, two groups of body weight are all growing steadily two treated animal weight ratios, model group than blank group body weight increase more rapid, but at the 1st week, the 2nd week, two groups of weight ratios comparatively, P>0.05, no significant difference; Animal feeding was to the 3rd week, the 4th week, 5 weeks, and comparatively, P<0.05, difference has statistical significance to two groups of weight ratios, and to the 6th week, comparatively, P<0.01, significant difference, had statistical significance to two groups of weight ratios, in table 1.
Before table 1 administration, two groups of body weight change compare (unit: g)
Note: compare with blank group
*p<0.05,
*p<0.01
Modeling the 6th weekend, the fasting glucose of model group, fasting insulin, insulin resistance index all raises, and compares, P<0.05 with blank group, significant difference, have statistical significance, insulin sensitivity index declines, P<0.05, compare with blank group, significant difference, has statistical significance, in table 2 and table 3.
A table 2 liang group fasting glucose change is compared (unit: mmol/L)
Note: compare with blank group
*p<0.05,
*p<0.01
Table 36 weekend two groups of insulins, insulin sensitivity index, insulin resistance indexs compare
Note: compare with blank group, * P<0.05, has statistical significance
2. GEGEN QINLIAN TANG component is on the glycometabolic impact of hyperglycemia model rat
2.1 animal groupings
By successful for modeling 110 SD male rats, 11 groups are divided into by random digits table: eight combinations (N1, N2, N3, N4, N5, N6, N7, N8) of each extract components proportioning of GEGEN QINLIAN TANG, Gegen Qinlian Tangyuan County side group (N9), metformin group (N10), model group (N11) according to body weight numbering.Each group is continued to give the high sugared high cholesterol diet of high fat, and original blank group (N12) continues to give normal diet, and totally 12 treated animals are often organized each 10, all given common drinking-water.
2.2 medicines and reagent source
Puerarin (Pue): the brilliant plant Science and Technology Ltd. in Xi'an, purity: 90%
Daidzein: the brilliant plant Science and Technology Ltd. in Xi'an, purity: 90%
Baicalin: the brilliant plant Science and Technology Ltd. in Xi'an, purity: 90%
Baicalin: the brilliant plant Science and Technology Ltd. in Xi'an, purity: 90%
Berberine: the brilliant plant Science and Technology Ltd. in Xi'an, purity: 90%
Glycyrrhizic acid: the brilliant plant Science and Technology Ltd. in Xi'an, purity: 90%
Liquirtin: the brilliant plant Science and Technology Ltd. in Xi'an, purity: 90%
GEGEN QINLIAN TANG: each taste Chinese medicine is purchased from Shaanxi Hospital of university of TCM.
Cholesterol: Hui Yuan biological product company limited of Pingdingshan City
Cholate: Hui Yuan biological product company limited of Pingdingshan City
CMC (sodium carboxymethyl cellulose): the Xinhe River, Hubei raw material company limited
Metformin hydrochloride (Met): Shanghai Pharmaceutical's letter friendship pharmacy head factory
10% glucose injection: Huayu (Wuxi) Pharmaceutical Co., Ltd.
Chloral hydrate: Shanghai chemical test company of Chinese Medicine group
The configuration of 2.3 medicines, reagent
In GEGEN QINLIAN TANG effectively and activity stronger have following 7 compounds: the flavonoid 1. deriving from Radix Puerariae: puerarin, daiazi; 2. the flavonoid of Radix Scutellariae is derived from: baicalin, baicalin; 3. the alkaloid of Rhizoma Coptidis is derived from: berberine; 4. the glycyrrhizic acid of Radix Glycyrrhizae, liquirtin is derived from.Concentration and mix proportion scheme as follows: four dose concentrations of puerarin are 50,100,250,500 (mg/kg), daidzein 10,25,50,100 (mg/kg), baicalin 10,25,50,100 (mg/kg), baicalin 10,25,50,100 (mg/kg), berberine 10,25,50,100 (mg/kg), glycyrrhizic acid 10,25,50,100 (mg/kg), liquirtin 10,25,50,100 (mg/kg).According to uniform Design principle, by seven of GEGEN QINLIAN TANG effective ingredient, with reference to each composition four concentration ranges, number of levels should be greater than because of prime number in principle, therefore adopt DPS data handling system, carry out uniform Design according to 7 factors, 8 levels, draw the scheme of optimization according to uniform Design scheme, as shown in Figures 2 and 3.
According to seven compositions of each drug extract of GEGEN QINLIAN TANG, four concentration ranges, N1-N8 forms distribution ratio as following table 4:
Table 4 GEGEN QINLIAN TANG each component compatibility concentration table (unit: mg/kgd)
N9: Gegen Qinlian Tangyuan County side group (Radix Puerariae: Radix Scutellariae: Rhizoma Coptidis: Radix Glycyrrhizae): GEGEN QINLIAN TANG, 9.0 (4.5:1.69:1.69:1.12) g/kgd, by each taste Chinese medicine of GEGEN QINLIAN TANG 90 (45:16.9:16.9:11.2) g, soak 20min respectively, be decocted first Radix Puerariae, reflux 20min, add all the other medicines again, reflux 30min, after medicinal liquid is poured out, add water secondary back 30min, merge medicinal liquid, decoction is concentrated into 100ml (according to 10ml/kgd concentrated traditional Chinese medicine), for subsequent use.
N10: metformin group, 200mg/kgd. configure metformin solution according to 10ml/kgd, by diformin tablet 2000mg, add 5 ‰ sodium carboxymethyl cellulose (CMC) solution and, to 100ml, stir.
The carboxymethylcellulose sodium solution of N11:5g/L, 10ml/kg gavage.
The carboxymethylcellulose sodium solution of N12:5g/L, 10ml/kg gavage.
The preparation of the carboxymethylcellulose sodium solution of 5 ‰: be slowly added to by 5g sodium carboxymethyl cellulose in 1000ml pure water, limit edged Glass rod stirs, and sodium carboxymethyl cellulose is fully dissolved, leaves standstill and uses after 1 day.
The preparation of 10% chloral hydrate: take 10 grams of chloral hydrate, by dissolved in purified water, then is diluted to 100 milliliters with pure water.
2.4 Testing index
2.4.1 ordinary circumstance observes the appetite of rat, body weight, behavior, hair and death condition, anesthetized animal after each rat weight at the end of experiment.
2.4.2 after fasting blood glucose (FPG) and the 12h of 2h glucose (PG-2h) animal fasting after the meal, cut tail and get blood, survey fasting glucose by blood glucose meter, after having surveyed, press 2.5g/kg dosage gavage with 25% G/W, survey (2h) blood glucose after the meal by blood glucose meter.
2.4.3 Diagnostic Value of Fasting Serum insulin
Survey Diagnostic Value of Fasting Serum insulin by euzymelinked immunosorbent assay (ELISA) (ELISA), modeling the 6th weekend, after fasting 12h, 10% chloral hydrate intraperitoneal injection of anesthesia, socket of the eye venous plexus is taken a blood sample, and gets anticoagulation, 4000r/min, centrifugal 5min, obtains blood plasma.Enzyme linked immunosorbent assay (Enzyme mono-linkedimmunosorbentassay, ELISA) measures Diagnostic Value of Fasting Serum insulin (Fastingseruminsulin, FINS) content.
2.4.4 glucose infusion rate (GIR) adopts positive sugared tongs technology
[28], Rat Fast is weighed after can't help water 12h, with 10% chloral hydrate solution (0.3ml/100g) intraperitoneal anesthesia.Rat being faced upward position is fixed on operating-table, keeps body temperature at about 37 DEG C, cuts off right skin of neck, operation is separated right external jugular vein, ligation distal end, otch, insert sebific duct (injecting 5U/ml heparin-saline solution in pipe in advance) to proximal part direction, intubate is fixed in ligation.From then on press 0.lml/l00g body weight in intubate and inject the anticoagulant of 1000u/ml heparin-saline solution, seal intubate.Separately cut off left neck (nearly center line) skin, isolate left common carotid, ligation distal end, clamps proximal part with bulldog clamp, otch, and insert sebific duct toward proximal part direction, intubate is fixed in ligation, open bulldog clamp.
Get mini three links, the port of export is connected with venous cannulation, and an entrance point connects with the constant flow pump of infusion of insulin, another entrance point is connected with peristaltic pump, the entrance point of peristaltic pump connects the microburet filling 10% glucose solution, treats that intubate operation and infusion device install, starts experiment.After measuring basal plasma glucose value (BBG), (configure with normal saline from vein with 4mu/kg constant speed gasing injection insulin solutions per minute, the concentration of insulin adjusts according to rat body weight), infusion 10% glucose solution simultaneously, every 5min from arterial blood extracting, blood glucose is measured by blood glucose meter, regulate GIR to maintain blood sugar level in the scope of BBG scholar 0.5mmol/L according to blood glucose value, when continuous 3 blood glucose values are all in above-mentioned scope, namely reach steady statue, under record stable state, the meansigma methods of last 6 GIR is for adding up contrast.
2.5 experimental result
2.5.1 ordinary circumstance administration is after 28 days, and each group rat normal activity, feed and drinking-water, reduce without appetite; model group (N11 group) the weight of animals increases obviously faster than blank group (N12 group); animal hair color is deepened, action delay of response, occurs significantly fat.Each group of body weight change is as following table 5:
Table 5 respectively group body weight change compares (unit: g)
Note: compare with N11 group
*p<0.05,
*p<0.01
At 6th weekend (before administration), comparatively, N1 to N10 organizes between each group and compares each group weight ratio, P>0.05, compare zero difference between each group, not statistically significant, N1 to N10 group compares with N11 group (model group), P<0.05, there were significant differences, and before administration is described, high sugared animal model grouping is harmonious good, after drug treatment, the difference of each group weight data causes primarily of medicine factor.Drug treatment is after 28 days, and N1 group all has reduction to N10 group body weight, and comparing with N11 group (model group) has notable difference, P<0.05, compares no significant difference (P>0.05) between each group body weight group.
2.5.2 on the impact of fasting glucose and 2h-plasma glucose
Fasting glucose (unit: mmol/L) respectively organized by table 6
Note: * and N11 (model group) compares, and P<0.05, * * and N11 (model group) compares, P<0.01.
2h-plasma glucose (unit: mmol/L) respectively organized by table 7
Note: * and N11 (model group) compares, and P<0.05, * * and N11 (model group) compares, P<0.01.
Experimental result shows: N11 group fasting glucose raises, and compares, have pole significant difference (P<0.01) with N12 group; N1 to N10 respectively organizes and compares with N11, all has significant difference (P<0.05); N1 to N10 organizes each group and compares with N12 group, there was no significant difference (P>0.05); N1 to N10 compares between respectively organizing, and N4 group reduces fasting glucose curative effect and is better than other each group, and be secondly N3 group, N9 group, N10 group curative effect are better than other each group (P<0.05).
Fill with the rear 2h blood glucose of sugar for each group to compare, N11 group 2hPh is higher than N12 group, have pole significant difference (P<0.01), N1 to N10 respectively organizes and compares with N11 (model group), all has significant difference (P<0.05); Each treatment group compares with blank group, there was no significant difference; N1 to N10 compares between respectively organizing, and be better than other each group with N4 group in reduction post-prandial glycemia curative effect, be secondly N3 group, N9 group, N10 group curative effect are better than other each group (P<0.05).
2.5.3 on the impact of glucose infusion rate and insulin
Table 8 and table 9 are referred on the impact of glucose infusion rate and insulin.
Serum insulin levels (mmol/L) respectively organized by table 8
Note: * and N11 (model group) compares, and P<0.05, * * and N11 (model group) compares, P<0.01.
Glucose infusion rate (ul/min) respectively organized by table 9
Note: * and N11 (model group) compares,
*p<0.05, # and N3 (model group) compare,
#p<0.05, Δ compares with N1, N2 group,
Δp<0.05.
The Data Comparison of table 5-table 9 can draw, the formula of best hypoglycemic drug is for press concentration proportioning puerarin 100mg/kg.d, daidzein 25mg/kg.d, baicalin 100mg/kg.d, baicalin 10mg/kg.d, berberine 10mg/kg.d, glycyrrhizic acid 5mg/kg.d, liquirtin 50mg/kg.d.The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, all any amendments done within the spirit and principles in the present invention, equivalent replacement and improvement etc., all should be included within protection scope of the present invention.
Claims (6)
1. a hypoglycemic pharmaceutical formulation, it is characterized in that: described pharmaceutical formulation comprises puerarin, daidzein, baicalin, baicalin, berberine, glycyrrhizic acid, liquirtin seven kinds of medicines, the dose concentration of above-mentioned puerarin is 50-500mg/kg.d, the dose concentration of daidzein is 10-100mg/kg.d, the dose concentration of baicalin is 10-100mg/kg.d, the dose concentration of baicalin is 10-100mg/kg.d, the dose concentration of berberine is 10-100mg/kg.d, the dose concentration of glycyrrhizic acid is 5-50mg/kg.d, the dose concentration of liquirtin is 10-100mg/kg.d.
2. the hypoglycemic pharmaceutical formulation of one according to claim 1, is characterized in that: described pharmaceutical formulation is made up of the crude drug of following matched proportion density:
The dose concentration of puerarin 100mg/kg.d, daidzein 25mg/kg.d, baicalin is 100mg/kg.d, the dose concentration of baicalin is 10mg/kg.d, the dose concentration of berberine is 10mg/kg.d, the dose concentration of glycyrrhizic acid is 5mg/kg.d, the dose concentration of liquirtin is 50mg/kg.d.
3. verify an experimental technique for blood sugar lowering composition formula, it is characterized in that: comprise following experimental procedure: 1) set up Hyperglycemia In Stz-induced Diabetic Rats model; 2) screening grouping; 3) Testing index; 4) analyze contrast and reach a conclusion.
4. a kind of experimental technique verifying blood sugar lowering composition formula according to claim 3, it is characterized in that: described step 1) in set up Hyperglycemia In Stz-induced Diabetic Rats model number of rats be 110, and be all male rat, above-mentioned 110 male rats are divided into 11 groups by random, often organize 10.
5. a kind of experimental technique verifying blood sugar lowering composition formula according to claim 3, it is characterized in that: described step 2) in screening grouping be divided into 12 groups, be respectively according to eight of GEGEN QINLIAN TANG each extract components proportioning combination N1-N8, Gegen Qinlian Tangyuan County side group N9, metformin group N10, model group N11, original blank group N12.
6. a kind of experimental technique verifying blood sugar lowering composition formula according to claim 3, is characterized in that: described step 3) in detect index be body weight, fasting glucose, 2h-plasma glucose, glucose filling rate, serum insulin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510902706.1A CN105497051B (en) | 2015-12-09 | 2015-12-09 | A kind of hypoglycemic pharmaceutical formulation and its experimental method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510902706.1A CN105497051B (en) | 2015-12-09 | 2015-12-09 | A kind of hypoglycemic pharmaceutical formulation and its experimental method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105497051A true CN105497051A (en) | 2016-04-20 |
| CN105497051B CN105497051B (en) | 2018-07-17 |
Family
ID=55705612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510902706.1A Expired - Fee Related CN105497051B (en) | 2015-12-09 | 2015-12-09 | A kind of hypoglycemic pharmaceutical formulation and its experimental method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105497051B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108743601A (en) * | 2018-07-06 | 2018-11-06 | 江苏大学 | A kind of scutelloside of anti-ulcerative colitis-radix scutellariae promotor composition and its preparation |
| CN112426418A (en) * | 2019-08-26 | 2021-03-02 | 中国中医科学院广安门医院 | Composition for treating diabetes and application thereof |
| CN113509505A (en) * | 2021-09-06 | 2021-10-19 | 康美华大基因技术有限公司 | Radix puerariae, radix scutellariae and rhizoma coptidis extract, preparation method, medicinal preparation and application |
| CN113694103A (en) * | 2021-09-06 | 2021-11-26 | 康美华大基因技术有限公司 | Traditional Chinese medicine extract without glycyrrhizic acid, preparation method, medicinal preparation and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102462834A (en) * | 2010-11-17 | 2012-05-23 | 仝小林 | Medicinal composition for controlling blood sugar of diabetic |
| CN105030940A (en) * | 2015-07-27 | 2015-11-11 | 西南民族大学 | Pharmaceutical composition for reducing blood glucose and application thereof |
-
2015
- 2015-12-09 CN CN201510902706.1A patent/CN105497051B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102462834A (en) * | 2010-11-17 | 2012-05-23 | 仝小林 | Medicinal composition for controlling blood sugar of diabetic |
| CN105030940A (en) * | 2015-07-27 | 2015-11-11 | 西南民族大学 | Pharmaceutical composition for reducing blood glucose and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 章军等: "综合评分法优化葛根芩连汤提取工艺", 《中国实验方剂学杂志》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108743601A (en) * | 2018-07-06 | 2018-11-06 | 江苏大学 | A kind of scutelloside of anti-ulcerative colitis-radix scutellariae promotor composition and its preparation |
| CN108743601B (en) * | 2018-07-06 | 2021-01-15 | 江苏大学 | Baicalin-baicalein composition for resisting ulcerative colitis and preparation thereof |
| CN112426418A (en) * | 2019-08-26 | 2021-03-02 | 中国中医科学院广安门医院 | Composition for treating diabetes and application thereof |
| CN113509505A (en) * | 2021-09-06 | 2021-10-19 | 康美华大基因技术有限公司 | Radix puerariae, radix scutellariae and rhizoma coptidis extract, preparation method, medicinal preparation and application |
| CN113694103A (en) * | 2021-09-06 | 2021-11-26 | 康美华大基因技术有限公司 | Traditional Chinese medicine extract without glycyrrhizic acid, preparation method, medicinal preparation and application |
| CN113694103B (en) * | 2021-09-06 | 2023-09-26 | 康美华大基因技术有限公司 | Traditional Chinese medicine extract without glycyrrhizic acid, preparation method, pharmaceutical preparation and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105497051B (en) | 2018-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105497051A (en) | Pharmaceutical formula capable of lowering blood glucose and experiment method of pharmaceutical formula | |
| CN106905390B (en) | The preparation technology and its detection method and purposes of a kind of black fruit fructus lycii anthocyanidin | |
| CN101623293A (en) | Medical composition for injection | |
| CN103494997B (en) | Traditional Chinese sophora flower medicine for treating hyperglycemia and diabetes | |
| Xue-Ying et al. | Regulatory effects of Poria on substance and energy metabolism in cold-deficiency syndrome compared with heat-deficiency syndrome in rats | |
| CN103705567B (en) | A kind of Dangguibuxue granules and preparation method thereof | |
| CN1879688B (en) | Preparation for treating wind-heat type cold, its preparation process and quality control method | |
| CN1977885B (en) | Antihepatitis medicinal composition | |
| CN102526656A (en) | Medicament or health-care food composition for preventing or/and treating erythremia | |
| CN104434941A (en) | Medicine composition for treating diabetes | |
| Yu et al. | Study on the effects of Chinese Materia medica processing on the hypoglycemic activity and chemical composition of anemarrhenae rhizoma | |
| CN104000896B (en) | A kind of Malus toringoides (Rehd.) Hughes extract and preparation method thereof and its purposes | |
| CN102565293A (en) | Detection method of bacterial endotoxins in pharmaceutical raw materials | |
| CN103893234B (en) | A kind of Sofflower injection, preparation method and content assaying method | |
| Qingya et al. | Effect of Ligustrum lucidum polysaccharide on immunity of immunosuppressed mice | |
| Jiang et al. | Network pharmacology combined with lipidomics to reveal the regulatory effects and mechanisms of Kangzao granules in the hypothalamus of rats with central precocious puberty | |
| CN101966251B (en) | Medicinal composition for preventing and treating bronchial asthma and preparation and application thereof | |
| CN105434886A (en) | Dendrobium officinale root extractive with blood-sugar reducing effect and uses thereof | |
| CN103599337A (en) | Garlic saponin liposome and preparation method thereof | |
| CN107182937B (en) | Construction method of in-vivo hypoxia-type diabetes mellitus early-stage animal model | |
| CN116870115B (en) | Composition with blood sugar reducing effect | |
| CN105213482A (en) | A kind of anti diabetes and kidney disease active substance liposome powder for injection and preparation method thereof | |
| CN104473943A (en) | Pharmaceutical composition used for treating diabetes | |
| CN104473948A (en) | Pharmaceutical composition used for treating diabetes | |
| CN104473935A (en) | Pharmaceutical composition used for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180717 Termination date: 20181209 |